(2R,3R,4S,5S,6R)-6-Hydroxymethyl-3-octyloxy-tetrahydro-pyran-2,4,5-triol | 142025-74-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4S,5S,6R)-6-Hydroxymethyl-3-octyloxy-tetrahydro-pyran-2,4,5-triol
• 英文别名: B-2-Octylglucoside；(2R,3R,4S,5S,6R)-6-(hydroxymethyl)-3-octoxyoxane-2,4,5-triol
• CAS: 142025-74-9
• 化学式: C₁₄H₂₈O₆
• 分子量: 292.373
• InChiKey: BVHPDIWLWHHJPD-RKQHYHRCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Pyrrolo-pyridine kinase modulators
  申请人：Arnold D. William

  公开号：US20060030583A1

  公开（公告）日：2006-02-09

  The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

  本发明提供了新型吡咯-吡啶激酶调节剂以及利用这些新型吡咯-吡啶激酶调节剂治疗由激酶活性介导的疾病的方法。
• AMPHIPATHIC COMPOUND HAVING NOVEL PENTA-SACCHARIDE HYDROPHILIC GROUP AND USE THEREOF
  申请人：Industry-University Cooperation Foundation Hanyang University Erica Campus

  公开号：US20190169218A1

  公开（公告）日：2019-06-06

  Disclosed are an amphipathic compound having a penta-saccharide hydrophilic group, a method of preparing the same, and a method of extracting, solubilizing, stabilizing, crystallizing or analyzing membrane proteins and membrane protein complexes using the same. In particular, since the compound has a high-density penta-saccharide hydrophilic group composed of five glucose units, the compound may have an excellent effect on crystallization of membrane proteins. In addition, since the hydrophilic group used in the amphipathic compound has a novel structure, the hydrophilic group may be applied to the development of various amphipathic molecules.

  披露了一种具有戊糖水基团的亲水性化合物，其制备方法以及使用该化合物提取、溶解、稳定、结晶或分析膜蛋白和膜蛋白复合物的方法。特别是，由于该化合物具有由五个葡萄糖单位组成的高密度戊糖水基团，该化合物可能对膜蛋白结晶具有显著效果。另外，由于在两亲性化合物中使用的亲水基团具有新颖的结构，该亲水基团可应用于各种两亲性分子的开发。
• [EN] TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE<br/>[FR] CONJUGUES DE TRIPARTITE CONTENANT UNE STRUCTURE INTERAGISSANT AVEC DES RADEAUX DE MEMBRANES CELLULAIRES ET LEUR UTILISATION
  申请人：JADOLABS GMBH

  公开号：WO2005097199A1

  公开（公告）日：2005-10-20

  The present invention relates to a compound comprising a tripartite structure in the format C-B-A or C'-B'-A' wherein moiety A and moiety A' is a raftophile, moiety B and moiety B' is a linker, moiety C and moiety C' is a pharmacophore; and wherein moiety B and B' is a linker which has a backbone of at least 8 carbon atoms and wherein one or more of said carbon atoms may be replaced by nitrogen, oxygen or sulfur. Furthermore, specific medical and pharmaceutical uses of the compounds of the invention are disclosed.

  本发明涉及一种包含三部分结构的化合物，其格式为C-B-A或C'-B'-A'，其中部分A和部分A'是亲脂性基团，部分B和部分B'是连接基团，部分C和部分C'是药用基团；其中部分B和B'是具有至少8个碳原子骨架的连接基团，其中所述碳原子中的一个或多个可被氮、氧或硫取代。此外，还披露了该发明化合物的特定医学和药用用途。
• PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
  申请人：Philippe Michel

  公开号：US20100028280A1

  公开（公告）日：2010-02-04

  The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

  该发明涉及一种直发角蛋白纤维的拉直过程，包括：(i)将至少两种变性剂含有的拉直组合物涂抹到角蛋白纤维上的步骤，(ii)使用加热装置将角蛋白纤维的温度升高至110至250°C的步骤。
• [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS<br/>[FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2003099805A1

  公开（公告）日：2003-12-04

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。